PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Device Removal”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 55 records · Page 3Linked to original sources
PubMed1987

Molding of the uterus following intrauterine contraceptive device removal: documentation by hysterosalpingography.

Intrauterine contraceptive devices (IUDs) distort the uterine cavity. We report 2 cases of endometrial molding demonstrated by hysterosalpingography (HSG) following removal of an IUD. Other processes may cause filling defects in the uterine cavity including inflammatory synechiae (Asherman's syndrome), tuberculosis, endometrial hyperplasia, and polyps. Whenever filling defects are seen, the history of IUD usage should be determined.

Adult↗
PubMed1981

Bacterial cultures from intrauterine devices removed from patients with pelvic inflammatory disease.

Bacterial cultures were obtained from intrauterine devices (IUD) removed from 274 patients admitted to the Department of Obstetrics and Gynecology of the University Central Hospital of Helsinki because of suspected pelvic inflammatory disease (PID), meno-metrorrhagia, pain or other conditions potentially caused by an IUD. A diagnosis of serious PID was made in 42 patients, mild PID in 119 patients, while 113 were found to have no infection. An association between positive cultures of beta-hemolytic streptococci and Escherichia coli and PID was found. Positive cultures of Neisseria gonorrhoeae were significantly correlated with PID. The risk of developing PID was significantly greater during the first month after insertion of the IUD than when more than 30 days had elapsed from insertion of the IUD. The significance of the microbes cultured from removal IUDs as causal agents of pelvic inflammatory disease is discussed.

Bacterial Infections↗
PubMed2004

The lost intrauterine device: removal by hysterectomy.

A case of migration of an intrauterine device (IUD) deep within the endometrium, presenting as heavy vaginal bleeding and abdominal pain, is discussed. The IUD had been in situ for 31 years. Standard retrieval techniques failed and removal necessitated hysterectomy. The complications of 'lost IUDs' are discussed and the need to enquire about removal in all women on approaching the menopause is emphasised.

Device Removal↗
PubMed1983

[Abdominal migration of intrauterine devices. Apropos of 4 devices removed using celioscopy].

The authors report four cases of abdominal migration of a Lippes Loop and describe the current features of the diagnostic approach and the essential role of ultrasound. They then discuss the therapeutic indications. In cases of complete migration, the device can be removed by laparoscopy or by laparotomy. In cases of incomplete migration, combined hysteroscopy and laparoscopy is performed to decide whether the device can be removed by hysteroscopy or by laparotomy.

Abdomen↗
PubMed2006

Synthetic blood group antigens for anti-A removal device and their interaction with monoclonal anti-A IgM.

Removal of blood group antibodies against the donor organ prior to ABO-incompatible transplantation can prevent episodes of hyperacute rejection. We are developing a specific antibody filter (SAF) device consisting of immobilized synthetic Atrisaccharide antigens conjugated to polyacrylamide (Atri-PAA) to selectively remove anti-A antibodies directly from whole blood. In this study, we evaluated eight anti-A IgM monoclonal antibodies (mAbs) using Enzyme-Linked Immunosorbent Assay (ELISA) to determine their specificity for binding to Atri-PAA. Five of the eight mAbs met our criteria for specificity by binding to Atri-PAA with at least five times greater affinity compared to the negative controls. These selected mAbs will be studied for their binding characteristics to Atri-PAA which will aid in the development of the SAF. The study of kinetics of antibody removal and quantification of antibody removal will be used in our mathematical model to maximize the antibody removal rate and binding capacity of the SAF.

Animals↗
PubMed2003

Successful treatment of pacemaker related endocarditis with acute embolic stroke without device removal.

Pacemaker related endocarditis is a rare potentially fatal condition, most commonly acquired during manipulation of the pacemaker system. Most patients have involvement of the right heart. Only rarely has involvement of the left-heart been documented. In the absence of controlled studies regarding management of such cases, many recommend complete removal of the pacing system along with intravenous antibiotics. We present a patient with documented pacemaker related left-sided endocarditis associated with an acute embolic stroke who was treated with antibiotics with complete recovery and its two-year follow up.

Aged↗
PubMed1998

Can intrauterine device removals for bleeding or pain be predicted at a one-month follow-up visit? A multivariate analysis.

From 4%-14% of intrauterine device (IUD) users have their IUD removed due to bleeding or pelvic pain in the first year of use. Past studies have analyzed whether baseline patient information can help predict such removals, but no previous analysis has examined whether information provided at the recommended 1-month follow-up visit could improve such predictions. Using data from an international multicenter randomized controlled trial, 89 women with removals for bleeding and pain after the 1-month visit were compared with 2536 continuing users. Logistic regression indicated several significant predictors of removal. Women reporting intermenstrual bleeding since last menses were nearly three times more likely to have removals for bleeding or pain (odds ratio [OR] 2.9; 95% confidence interval [CI] 1.4-5.9). Similarly, those complaining of excessive menstrual flow were 3.5 times more likely to have removals within 12 months (95% CI 1.4-9.2). Women reporting these menstrual problems during scheduled revisits may benefit from counseling and treatment with nonsteroidal anti-inflammatory drugs (NSAID).

Adolescent↗
PubMed1993

Copper release from copper intrauterine devices removed after up to 8 years of use.

We studied the copper-releasing ability, weight and microscopic appearance of 2 copper-bearing intrauterine devices (IUDs), Copper-T Cu 200 (CuT) and Nova-T Cu 200 Ag (NovaT), after they had been in utero for up to 8 years. In addition, we studied whether IUDs removed from pregnant women showed different copper release. We found that IUD weight was a linear, negative function of duration of use, and that less than 20% of total copper would be released over a period of 8 years. The average copper-releasing ability was significantly higher for CuT than for NovaT (82.6 +/- 6.4 vs. 42.7 +/- 2.6 micrograms/day). The copper release was constant and thus unrelated to duration of use. Copper-releasing ability was similar in IUDs removed from pregnant and non-pregnant women. Fragmentation or minor defects only occurred in 3% of the IUDs and no correlation was found between deposits or corrosion and copper release rates. We conclude that CuT and NovaT both have constant copper release for at least 5-6 years and that the useful life-span probably can be prolonged to 6-8 years or more.

Copper↗
PubMed2026

Advances in fragment removal devices in ureteroscopy: up-to-date review.

PURPOSE OF REVIEW: The development of laser lithotripsy for flexible ureteroscopy (fURS) has improved access and the ability to fragment renal stones. A common challenge for endourologists is managing the residual fragments (RF) of these stones. These RFs are associated with higher complication rates and the need for reinterventions and could serve as a focus for future stone formation. We aim to summarize recent technological advancements that increase the likelihood of removing more RFs and ultimately achieving stone-free status (SFS). RECENT FINDINGS: New technologies expand upon existing devices or create novel techniques, improving efficiency and increasing the volume of RF that can be extracted. Improvements to stone-grabbing baskets enable more controlled passes, reducing damage and complications. The flexible and navigable suction ureteric access sheath (FANS) builds on the traditional ureteral access sheath (UAS) by offering greater manoeuvrability and RF extraction from difficult anatomical locations. The development of urothelial-safe hydrogels provides an effective way to group and remove fragments. Additionally, magnetic hydrogels show promise for extracting tiny particles from hidden renal structures, advancing toward an ideal SFS. The Spinner-Induced Synergistic Circulation and Spiral Flow device also shows potential for rapidly removing numerous fragments. SUMMARY: Novel technological advancements build upon existing technologies or develop new methods of maximizing RF extraction while maintaining the balance of suction, irrigation, intrarenal pressure, and temperature - the Quadrifecta of retrograde intrarenal surgery (RIRS).

Humans↗
PubMed1999

High-energy pulsed light source hair removal device used to evaluate the onset of action of a new topical anesthetic.

BACKGROUND: Topical anesthetic agents are widely used to mitigate the pain associated with laser and high-energy pulsed light source hair removal. OBJECTIVE: To evaluate the relative efficacy and onset of action of a new topical anesthetic agent, ELA-Max cream (lidocaine 4%), relative to a widely used agent, EMLA cream (lidocaine 2.5%/prilocaine 2.5%). METHODS: ELA-Max and EMLA were applied to the forearms of 10 unblinded test subjects. The EMLA-treated sites were occluded for 1.5 hours prior to testing. The ELA-Max-treated sites were unoccluded and the cream was applied immediately prior to testing. Pulses from an Epilight high-energy pulsed light source were then administered 1.5 hours after occlusion with EMLA and in 5-minute intervals after application of ELA-Max. Pain scores were recorded on a visual analog scale (VAS). RESULTS: Six of 10 patients reported some anesthetic effect from ELA-Max after 5 minutes of unoccluded skin contact. Seven of 10 subjects reported maximal pain control 20 minutes after application of unoccluded ELA-Max, roughly equivalent to EMLA after 1.5 hours of occlusion. CONCLUSION: ELA-Max is an effective topical anesthetic agent comparable to EMLA under occlusion. It appears to be faster acting than EMLA, and along with its effectiveness without occlusion, may be an easier agent to use.

Anesthetics, Combined↗